BCR-ABL1 inhibitor · small molecule
ponatinib
0 active trials across 7 of our biomarkers, targeting BCR-ABL1 (pan). Not approved for any biomarker on marked.bio yet.
Also known as AP24534, Iclusig.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| ALK fusion | 0 | 1 | – |
| FGFR2 fusion or rearrangement | 0 | 2 | – |
| FGFR3 alteration (mutation or fusion) | 0 | 1 | – |
| FLT3 mutation (ITD/TKD) | 0 | 3 | – |
| KRAS G12C | 0 | 1 | – |
| KRAS G12D | 0 | 1 | – |
| RET fusion or mutation | 0 | 1 | – |
Trials
0 of 8 trials shown
-
Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients
…lusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients
FLT3 mutation (ITD/TKD)Leukemia, Myeloid, Acute
-
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
KRAS mutation
KRAS G12CKRAS G12DNon Small Cell Lung Cancer, KRAS Gene Mutation
-
Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
ponatinibazacitidine
Patients should have a FLT3 mutation, either ITD or kinase domain mutation or activation loop mutation.
FLT3 mutation (ITD/TKD)Leukemia, FLT3-Mutated Acute Myeloid Leukemia, FLT3-Mutated High-Risk Myelodysplastic Syndrome
-
Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
…er that is refractory or intolerant to gemcitabine or fluoropyrimidine based therapy with FGFR2 fusion \[using next-gen sequencing assays (such as Foundation One) or fluorescent in situ hybrid…
FGFR2 fusion or rearrangementMalignant Hepatobiliary Neoplasm
-
Ponatinib for FLT3-ITD Acute Myelogenous Leukemia
ponatinibcytarabine
Intermediate risk karyotype with FLT3-ITD activating mutant detected at diagnosis (mutant FLT3/wild-type allelic ratio higher than …
FLT3 mutation (ITD/TKD)Acute Myeloid Lukemia
-
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
…or both epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements
ALK fusionAdenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
-
Ponatinib in Advanced NSCLC w/ RET Translocations
Molecular confirmation of a RET translocation
RET fusion or mutationNon Small Cell Lung Cancer
-
Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementEndometrial Neoplasms
No trials match these filters.